Federal Register / Vol. 76, No. 1 / Monday, January 3, 2011 / Notices 161 

Dated: December 27, 2010,, 

Robert Hendricks, 

Director, Division of Policy and Information 

Coordination. 

[FR Doc. 2010–33062 Filed 12–30–10; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The concept meeting, 

proposals and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the contract proposals, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel. Contraceptive 

Clinical Trials Network. 

Date: January 12, 2011. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate concept 

review. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Room 2A01, Rockville, 

MD 20852. (Telephone Conference Call). 

Contact Person: Sathasiva B. Kandasamy, 

PhD, Scientific Review Administrator, 

Division of Scientific Review, National 

Institute of Child Health and Human 

Development, 6100 Executive Boulevard, 

Rockville, Md 20892–9304. (301) 435–6680. 

skandasa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment program, National 

Institutes of Health, HHS) 

Dated: December 27, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–33067 Filed 12–30–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel. 

Date: January 10, 2011. 

Time: 12:45 p.m. to 3 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6100 

Executive Boulevard, Room 2A01, Rockville, 

MD 20852. (Telephone Conference). 

Contact Person: Sathasiva B. Kandasamy, 

PhD, Scientific Review Administrator, 

Division of Scientific Review, National 

Institute of Child Health and Human 

Development, 6100 Executive Boulevard, 

Rockville, MD 20892–9304. (301) 435–6680. 

skandasa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: December 27, 2010. 

Jennifer S. Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–33068 Filed 12–30–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of Laboratories and 

Instrumented Initial Testing Facilities 

Which Meet Minimum Standards To 

Engage in Urine Drug Testing for 

Federal Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies Federal 

agencies of the Laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). The 

Mandatory Guidelines were first 

published in the Federal Register on 

April 11, 1988 (53 FR 11970), and 

subsequently revised in the Federal 

Register on June 9, 1994 (59 FR 29908); 

September 30, 1997 (62 FR 51118); 

April 13, 2004 (69 FR 19644); November 

25, 2008 (73 FR 71858); December 10, 

2008 (73 FR 75122); and on April 30, 

2010 (75 FR 22809). 

A notice listing all currently certified 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) is published in 

the Federal Register during the first 

week of each month. If any Laboratory/ 

IITF’s certification is suspended or 

revoked, the Laboratory/IITF will be 

omitted from subsequent lists until such 

time as it is restored to full certification 

under the Mandatory Guidelines. 

If any Laboratory/IITF has withdrawn 

from the HHS National Laboratory 

Certification Program (NLCP) during the 

past month, it will be listed at the end 

and will be omitted from the monthly 

listing thereafter. 

This notice is also available on the 

Internet at http:// 

www.workplace.samhsa.gov and http:// 

www.drugfreeworkplace.gov. 

FOR FURTHER INFORMATION CONTACT: Mrs. 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, Room 2– 

1042, One Choke Cherry Road, 

Rockville, Maryland 20857; 240–276– 

2600 (voice), 240–276–2610 (fax). 

SUPPLEMENTARY INFORMATION: The 

Mandatory Guidelines were initially 

developed in accordance with Executive 

Order 12564 and section 503 of Public 

Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs’’, as amended in the 

revisions listed above, requires {or set} 

strict standards that Laboratories and 


jlentini on DSKJ8SOYB1PROD with NOTICES
162 Federal Register / Vol. 76, No. 1 / Monday, January 3, 2011 / Notices 

* The Standards Council of Canada (SCC) voted 

to end its Laboratory Accreditation Program for 

Substance Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that program were 

accredited to conduct forensic urine drug testing as 

required by U.S. Department of Transportation 

(DOT) regulations. As of that date, the certification 

of those accredited Canadian laboratories will 

continue under DOT authority. The responsibility 

for conducting quarterly performance testing plus 

periodic on-site inspections of those LAPSAaccredited laboratories was transferred to the U.S. 

HHS, with the HHS’ NLCP contractor continuing to 

have an active role in the performance testing and 

laboratory inspection processes. Other Canadian 

laboratories wishing to be considered for the NLCP 

may apply directly to the NLCP contractor just as 

U.S. laboratories do. 

Upon finding a Canadian laboratory to be 

qualified, HHS will recommend that DOT certify 

the laboratory (Federal Register, July 16, 1996) as 

meeting the minimum standards of the Mandatory 

Guidelines published in the Federal Register on 

April 30, 2010 (75 FR 22809). After receiving DOT 

certification, the laboratory will be included in the 

monthly list of HHS-certified laboratories and 

participate in the NLCP certification maintenance 

program. 

Instrumented Initial Testing Facilities 

(IITF) must meet in order to conduct 

drug and specimen validity tests on 

urine specimens for Federal agencies. 

To become certified, an applicant 

Laboratory/IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a Laboratory/IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) in the applicant 

stage of certification are not to be 

considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A Laboratory/ 

IITF must have its letter of certification 

from HHS/SAMHSA (formerly: HHS/ 

NIDA) which attests that it has met 

minimum standards. 

In accordance with the Mandatory 

Guidelines dated November 25, 2008 

(73 FR 71858), the following 

Laboratories and Instrumented Initial 

Testing Facilities (IITF) meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Instrumented Initial Testing Facilities 

(IITF) 

None. 

Laboratories 

ACL Laboratories, 8901 W. Lincoln 

Ave., West Allis, WI 53227. 414–328– 

7840/800–877–7016. (Formerly: 

Bayshore Clinical Laboratory.) 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624. 

585–429–2264. 

Advanced Toxicology Network, 3560 

Air Center Cove, Suite 101, Memphis, 

TN 38118. 901–794–5770/888–290– 

1150. 

Aegis Analytical Laboratories, 345 Hill 

Ave., Nashville, TN 37210. 615–255– 

2400. (Formerly: Aegis Sciences 

Corporation, Aegis Analytical 

Laboratories, Inc.) 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053. 504–361–8989/ 

800–433–3823. (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236. 804–378–9130. (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Baptist Medical Center-Toxicology 

Laboratory, 11401 I–30, Little Rock, 

AR 72209–7056. 501–202–2783. 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center.) 

Clinical Reference Lab, 8433 Quivira 

Road, Lenexa, KS 66215–2802. 800– 

445–6917. 

Doctors Laboratory, Inc., 2906 Julia 

Drive, Valdosta, GA 31602. 229–671– 

2281. 

DrugScan, Inc., P.O. Box 2969, 1119 

Mearns Road, Warminster, PA 18974. 

215–674–9310. 

DynaLIFE Dx,* 10150–102 St., Suite 

200, Edmonton, Alberta, Canada T5J 

5E2. 780–451–3702/800–661–9876. 

(Formerly: Dynacare Kasper Medical 

Laboratories.) 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655. 662– 

236–2609. 

Gamma-Dynacare Medical 

Laboratories,* A Division of the 

Gamma-Dynacare Laboratory 

Partnership, 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4. 519– 

679–1630. 

Laboratory Corporation of America 

Holdings, 7207 N. Gessner Road, 

Houston, TX 77040. 713–856–8288/ 

800–800–2387. 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869. 908–526–2400/800–437–4986. 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 Alexander Drive, 

Research Triangle Park, NC 27709. 

919–572–6900/800–833–3984. 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group.) 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671. 866–827–8042/ 

800–233–6339. (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center.) 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219. 913–888–3927/800–873–8845. 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.) 

Maxxam Analytics,* 6740 Campobello 

Road, Mississauga, ON, Canada L5N 

2L8. 905–817–5700. (Formerly: 

Maxxam Analytics Inc., NOVAMANN 

(Ontario), Inc.) 

MedTox Laboratories, Inc., 402 W. 

County Road D, St. Paul, MN 55112. 

651–636–7466/800–832–3244. 

MetroLab-Legacy Laboratory Services, 

1225 NE 2nd Ave., Portland, OR 

97232. 503–413–5295/800–950–5295. 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417. 612–725– 

2088. 

National Toxicology Laboratories, Inc., 

1100 California Ave., Bakersfield, CA 

93304. 661–322–4250/800–350–3515. 

One Source Toxicology Laboratory, Inc., 

1213 Genoa-Red Bluff, Pasadena, TX 

77504. 888–747–3774. (Formerly: 

University of Texas Medical Branch, 

Clinical Chemistry Division; UTMB 

Pathology-Toxicology Laboratory.) 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311. 

800–328–6942. (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory.) 

Pathology Associates Medical 

Laboratories, 110 West Cliff Dr., 

Spokane, WA 99204. 509–755–8991/ 

800–541–7891x7. 

Phamatech, Inc., 10151 Barnes Canyon 

Road, San Diego, CA 92121. 858–643– 

5555. 

Quest Diagnostics Incorporated, 1777 

Montreal Circle, Tucker, GA 30084. 

800–729–6432. (Formerly: SmithKline 

Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories.) 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403. 

610–631–4600/877–642–2216. 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories.) 

Quest Diagnostics Incorporated, 8401 

Fallbrook Ave., West Hills, CA 91304. 

800–877–2520. (Formerly: SmithKline 

Beecham Clinical Laboratories.) 

S.E.D. Medical Laboratories, 5601 Office 

Blvd., Albuquerque, NM 87109. 505– 

727–6300/800–999–5227. 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 76, No. 1 / Monday, January 3, 2011 / Notices 163 

South Bend Medical Foundation, Inc., 

530 N. Lafayette Blvd., South Bend, 

IN 46601. 574–234–4176 x1276. 

Southwest Laboratories, 4625 E. Cotton 

Center Boulevard, Suite 177, Phoenix, 

AZ 85040. 602–438–8507/800–279– 

0027. 

St. Anthony Hospital Toxicology 

Laboratory, 1000 N. Lee St., 

Oklahoma City, OK 73101. 405–272– 

7052. 

STERLING Reference Laboratories, 2617 

East L Street, Tacoma, Washington 

98421, 800–442–0438. 

Toxicology & Drug Monitoring 

Laboratory, University of Missouri 

Hospital & Clinics, 301 Business Loop 

70 West, Suite 208, Columbia, MO 

65203. 573–882–1273. 

Toxicology Testing Service, Inc., 5426 

N.W. 79th Ave., Miami, FL 33166. 

305–593–2260. 

U.S. Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235. 301–677–7085. 

Dated: December 15, 2010. 

Elaine Parry, 

Director, Office of Management, Technology, 

and Operations, SAMHSA. 

[FR Doc. 2010–32908 Filed 12–30–10; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

Agency Information Collection 

Activities: CBP Regulations Pertaining 

to Customs Brokers 

AGENCY: U.S. Customs and Border 

Protection, Department of Homeland 

Security. 

ACTION: 30-Day notice and request for 

comments; Extension of an existing 

information collection: 1651–0034. 

SUMMARY: U.S. Customs and Border 

Protection (CBP) of the Department of 

Homeland Security will be submitting 

the following information collection 

request to the Office of Management and 

Budget (OMB) for review and approval 

in accordance with the Paperwork 

Reduction Act: CBP Regulations 

Pertaining to Customs Brokers (19 CFR 

part 111). This is a proposed extension 

of an information collection that was 

previously approved. CBP is proposing 

that this information collection be 

extended with no change to the burden 

hours or to the information being 

collected. This document is published 

to obtain comments from the public and 

affected agencies. This proposed 

information collection was previously 

published in the Federal Register (75 

FR 67094) on November 1, 2010, 

allowing for a 60-day comment period. 

This notice allows for an additional 30 

days for public comments. This process 

is conducted in accordance with 5 CFR 

1320.10. 

DATES: Written comments should be 

received on or before February 2, 2011. 

ADDRESSES: Interested persons are 

invited to submit written comments on 

this proposed information collection to 

the Office of Information and Regulatory 

Affairs, Office of Management and 

Budget. Comments should be addressed 

to the OMB Desk Officer for Customs 

and Border Protection, Department of 

Homeland Security, and sent via 

electronic mail to 

oira_submission@omb.eop.gov or faxed 

to (202) 395–5806. 

SUPPLEMENTARY INFORMATION: U.S. 

Customs and Border Protection (CBP) 

encourages the general public and 

affected Federal agencies to submit 

written comments and suggestions on 

proposed and/or continuing information 

collection requests pursuant to the 

Paperwork Reduction Act (Pub. L. 104– 

13). Your comments should address one 

of the following four points: 

(1) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency/component, 

including whether the information will 

have practical utility; 

(2) Evaluate the accuracy of the 

agencies/components estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(3) Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

(4) Minimize the burden of the 

collections of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

techniques or other forms of 

information. 

Title: CBP Regulations Pertaining to 

Customs Brokers (19 CFR Part 111). 

OMB Number: 1651–0034. 

Form Numbers: CBP Forms 3124 and 

3124E. 

Abstract: The information contained 

in part 111 of the CBP regulations 

governs the licensing and conduct of 

customs brokers. Specifically, an 

individual who wishes to take the 

broker exam would complete CBP Form 

3124E, ‘‘Application for Customs Broker 

License Exam’’; or to apply for a broker 

license, CBP Form 3124, ‘‘Application 

for Customs Broker License’’ must be 

completed. The procedures to request a 

local or national broker permit can be 

found in 19 CFR 111.19, and a triennial 

report is required under 19 CFR 111.30. 

The information collected from customs 

brokers is provided for by 19 U.S.C. 

1641. CBP Forms 3124 and 3124E may 

be found at http://www.cbp.gov/xp/ 

cgov/toolbox/forms/. Further 

information about the customs broker 

exam and how to apply for it may be 

found at http://www.cbp.gov/xp/cgov/ 

trade/trade_programs/broker/ 

broker_exam/notice_of_exam.xml. 

Current Actions: This submission is 

being made to extend the expiration 

date with no change to the burden hours 

or to this collection of information. 

Type of Review: Extension (without 

change). 

Affected Public: Businesses, 

Individuals. 

CBP Form 3124E, ‘‘Application for 

Customs Broker License Exam 

Estimated Number of Respondents: 

2,300. 

Total Number of Estimated Annual 

Responses: 2,300. 

Estimated Time per Response: 1 hour. 

Estimated Total Annual Burden 

Hours: 2,300. 

Estimated Total Annual Cost to the 

Public: $466,000. 

CBP Form 3124, ‘‘Application for 

Customs Broker License’’ 

Estimated Number of Respondents: 

300. 

Total Number of Estimated Annual 

Responses: 300. 

Estimated Time per Response: 1 hour. 

Estimated Total Annual Burden 

Hours: 300. 

Triennial Report (19 CFR 111.30) 

Estimated Number of Respondents: 

3,833. 

Total Number of Estimated Annual 

Responses: 3,833. 

Estimated Time per Response: .5 

hours. 

Estimated Total Annual Burden 

Hours: 1,917. 

Estimated Total Annual Cost to the 

Public: $383,300. 

National Broker Permit Application 

(19 CFR 111.19) 

Estimated Number of Respondents: 

500. 

Total Number of Estimated Annual 

Responses: 500. 

Estimated Time per Response: 1 hour. 

Estimated Total Annual Burden 

Hours: 500. 

Estimated Total Annual Cost to the 

Public: $112,500. 

If additional information is required 

contact: Tracey Denning, U.S. Customs 

and Border Protection, Regulations and 

Rulings, Office of International Trade, 

799 9th Street, NW., 5th Floor, 


jlentini on DSKJ8SOYB1PROD with NOTICES